Autolus Ltd. is looking to get back on track after numerous setbacks in its goal to produce the next generation of CAR-T products.
The UK-based biotech’s problems have been reflected in a share price which has lost nearly
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?